Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “outperform” rating reaffirmed by equities researchers at Royal Bank of Canada in a report issued on Monday, Benzinga reports. They presently have a $1,229.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 14.73% from the company’s previous close.

Several other equities analysts have also commented on REGN. Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.96.

Regeneron Pharmaceuticals Trading Up 0.7 %

REGN opened at $1,071.19 on Monday. The stock has a market capitalization of $118.03 billion, a PE ratio of 31.65, a P/E/G ratio of 2.18 and a beta of 0.13. The firm’s fifty day moving average price is $974.69 and its 200 day moving average price is $947.43. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. As a group, research analysts expect that Regeneron Pharmaceuticals will post 37.12 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $28,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.